Table 1.

Clinical Trials of Oral TYK2 Inhibitors in IBD

Agent	MOA	Disease*	Clinical Trial	Patients, n	Study Design	Primary Endpoint	Projected Completion
Brepocitinib	Dual TYK2/JAK1 inhibitor, binds to the active site in the catalytic domain	UC	ClinicalTrials.gov identifier: NCT02958865	360	Phase 2b, double-blind, randomized, placebo-controlled	Clinical remission at week 8	May 2021
		CD	ClinicalTrials.gov identifier: NCT03395184	250	Phase 2a, double-blind, randomized, placebo-controlled	Endoscopic improvement at week 12, safety up to week 68	November 2022
PF-06826647	Dual TYK2/JAK2 inhibitor, binds to the active site in the catalytic domain	UC	ClinicalTrials.gov identifier: NCT04209556	202	Phase 2b, double-blind, randomized, placebo-controlled	Endoscopic improvement at week 8, safety up to week 60	Withdrawn
Deucravacitinib	TYK2 inhibitor, binds to the regulatory (pseudokinase) domain (allosteric inhibition)	UC	LATTICE-UC; ClinicalTrials.gov identifier: NCT03934216	120	Phase 2, double-blind, randomized, placebo-controlled	Clinical remission at week 12	July 2023
		CD	LATTICE-CD; ClinicalTrials.gov identifier: NCT03599622	240	Phase 2, double-blind, randomized, placebo-controlled	Clinical remission at week 12, endoscopic response at week 12	March 2024

*Patients were required to have moderate to severe disease.

MOA indicates mechanism of action.